Dharminder Chahal

Dharminder Chahal is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, developing novel therapeutics and early diagnostic tests for cardiovascular diseases. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Mr. Chahal has built an extensive network in the life science industry and a strong track record in direct involvement of complex corporate transactions including the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Octoplus to Dr. Reddy’s. As a board member or advisor he has been and still is active for several European companies in the field of life sciences.

At present, Mr. Chahal is a supervisory board member of BioInvent, Sweden, a supervisory board member of VitalneXt, an advisory board member of BioGeneration Ventures II, Thuja Capital Fund I as well as Gilde Healthcare Funds II and III, and observer on the supervisory board of Innate Pharma, France. Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co, Robeco and Van Herk Investments. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).